Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
BLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.40 - 17.40
Previous CloseN/A
Volume20.50M
Average Volume (3M)3.98M
Market Cap
53.71M
Enterprise Value6.86M
Total Cash (Recent Filing)28.16M
Total Debt (Recent Filing)12.60M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Dec 01, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,557,611,000
10 Day Avg. Volume3,936,013
30 Day Avg. Volume3,980,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2.00Price Target Upside-4.76% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.40 and its highest was 17.40 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is 53.71M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Dec 01, 2025 which is in 80 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Aug 14, 2025. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.338 by 0.338.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.34.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,557,611,000 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.338. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.